US-based molecular diagnostics company Biocept has signed a provider agreement for Alliance Global to market and distribute its Target Selector liquid biopsy tests in the UAE, certain Middle East countries, North & Sub-Saharan Africa and the South East Asia (MEAA) region.
Under the agreement, the diagnostics company will carry out all diagnostic testing services in its San Diego-based laboratory, while Alliance Global will be responsible for sales, marketing, distribution and reimbursement.
The Target Selector platform is designed to capture and analyse related molecular markers in circulating tumour cells (CTCs), as well as plasma (ctDNA).
Alliance Global commercial operations group director Nassim-Marie Hambouz said: “Offering Biocept’s novel liquid biopsy tests supports our commitment to bringing innovative biomedical products and services to emerging markets, and this agreement reflects Alliance Global’s focus on the growing clinical genomics sector in the MEAA region.
“A major focus will be to use Biocept’s testing services to support global biopharmaceutical companies in qualifying patients for their targeted therapies.”
In all the tests performed to date, the liquid biopsy technology platform is said to have successfully detected cancer mutations and alterations, allowing disease diagnosis and treatment decisions.
Biocept president and CEO Michael Nall said: “We are enthusiastic about the opportunities with a capable partner in this important region, and given our strong global intellectual property position, we will continue to be opportunistic in seeking to develop the market for our liquid biopsy solutions internationally.”
Target Selector tests are currently available across 17 countries under eight international agreements signed by the company.
